Title: Combination of Serological Biomarkers and Clinical Features to predict Mucosal Healing
in Crohn’s Disease: A Multicenter Cohort Study
Version: 2 Date: 06 Apr 2022
Reviewer's report:
I have read with great interest this manuscript. It is interesting and well written.
Excellent statistical analyses.
I have a few minor suggestions:
- Introduction: "We analyzed the pre-treatment and post-treatment data individually and
explored their relationship with MH after treatment in patients with CD." I think that here
and in the entire manuscript the authors need to better specify which kind of treatment.
Immunomodulators, steroids and IFX? Only IFX? This point is not clear.
- Please, in the Discussion Section specify as a limitation that this is a retrospective study (there
could be errors in storing serums and collecting data).
Title: Combination of Serological Biomarkers and Clinical Features to predict Mucosal Healing
in Crohn’s Disease: A Multicenter Cohort Study
Version: 2 Date: 06 Apr 2022
Reviewer's report:
I have read with great interest this manuscript. It is interesting and well written.
Excellent statistical analyses.
I have a few minor suggestions:
- Introduction: "We analyzed the pre-treatment and post-treatment data individually and
explored their relationship with MH after treatment in patients with CD." I think that here
and in the entire manuscript the authors need to better specify which kind of treatment.
Immunomodulators, steroids and IFX? Only IFX? This point is not clear.
- Please, in the Discussion Section specify as a limitation that this is a retrospective study (there
could be errors in storing serums and collecting data).
Please review this paper.
user
Title: Combination of Serological Biomarkers and Clinical Features to predict Mucosal Healing
in Crohn’s Disease: A Multicenter Cohort Study
Version: 2 Date: 06 Apr 2022
Reviewer's report:
I have read with great interest this manuscript. It is interesting and well written.
Excellent statistical analyses.
I have a few minor suggestions:
- Introduction: "We analyzed the pre-treatment and post-treatment data individually and
explored their relationship with MH after treatment in patients with CD." I think that here
and in the entire manuscript the authors need to better specify which kind of treatment.
Immunomodulators, steroids and IFX? Only IFX? This point is not clear.
- Please, in the Discussion Section specify as a limitation that this is a retrospective study (there
could be errors in storing serums and collecting data).
assistant